The Scottish Medicines Consortium (SMC has published new guidelines approving NHS funding for medicines for breast cancer and Hodgkin’s lymphoma.
News
SGLT-2 inhibitors cut risk of death in diabetics, data shows
AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
Biogen buys Pfizer’s schizophrenia drug
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
Hikma/Vectura’s generic Advair delayed in the US
US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline’s asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
Sanofi, Regeneron to cut price of Praluent
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
AZ announces results delay for key lung cancer trial
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
NICE minded to reject Keytruda for classical Hodgkin lymphoma
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.
EU expands scope of GSK/Innoviva’s asthma inhaler
The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach.
PharmaTimes Clinical Researcher of the Year – The Americas: Finalists to be announced soon!
Clinical researchers in the Americas have submitted essays for this year’s competition and on 15 March, the authors and finalists will be identified at a meeting of the executive steering group.
US panel backs Pfizer’s Xeljanz for ulcerative colitis
US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
Cytox gets £800,00 from Innovate UK
Cytox has been awarded funding from Innovate UK for the clinical evaluation of its pioneering approach to Alzheimer’s disease risk assessment.
RCEM calls for public action on A&E crisis
The Royal College of Emergency Medicine is urging patients to lobby MPs for action to address the “serious challenges” facing Emergency Departments across the UK.
Finalists announced!
Following a meeting of the executive steering group, PharmaTimes Media is delighted to reveal the 2018 International Clinical Researcher of the Year finalists…
UCB’s Vimpat gets NHS green light in Wales
The All Wales Medicines Strategy Group has approved NHS funding for the use of UCB’s Vimpat in children with epilepsy.
NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
